We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSLN
RNS Number : 7816D
Silence Therapeutics PLC
02 February 2018
Grant of share options and restricted stock units
2(nd) February 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has granted nominal cost share options ("Options") to certain of its executive directors to acquire a total of 169,921 ordinary shares of 5.0p each in the capital of the Company ("Ordinary Shares") under the Silence Therapeutics plc 2018 Long Term Incentive Plan. The Company has also made a grant of nominal cost restricted stock units ('RSUs') to the Non-Executive Directors under the Silence Therapeutics plc 2018 Non-Employee Long Term Incentive Plan. These two new plans were approved by the Board of Directors on 2(nd) February 2018. Details of both grants are summarised below
Grant of Share Options:
Hot Features
Premium
Director Position Options Awarded Total Options
Held
Ali Mortazavi CEO 88,620 4,058,920
---------- ---------------- --------------
David Ellam CFO 81,301 593,676
---------- ---------------- --------------
These nominal cost options will vest in full on 1(st) February 2021. The Options are subject to achievement of certain performance conditions within the three years from grant, based on 34% vesting for a share price of GBP2.70, a further 33% vesting for a share price of GBP3.00, and the final 33% for a share price of GBP3.40. The share price must be maintained for a period of 30 continuous days. The Options are exercisable over the period of 7 years from the date of vesting. Claw-back and malus provisions apply. There is a one-year holding period.
Nominal cost options over 458,766 Ordinary Shares were granted to other employees of the Company. These options have a hurdle price of 198.0 pence per share. They will vest in full on 1(st) February 2021 subject to the average closing price of the prior 30 continuous days being above 198.0 pence per share.
Award of Restricted Stock Units
Director Position Options Awarded Total Options
Held
Non-Executive
Annalisa Jenkins Chair 1,626 1,626
--------------- ---------------- --------------
Non-Executive
Alistair Gray Director 1,626 1,626
--------------- ---------------- --------------
Non-Executive
Stephen Parker Director 1,626 1,626
--------------- ---------------- --------------
Non-Executive
Andy Richards Director 1,626 1,626
--------------- ---------------- --------------
Each RSU entitles the holder to subscribe for an Ordinary Share at a subscription price of 5 pence per Ordinary Share. The RSUs have a vesting period of one year and no performance conditions. The RSUs granted will vest on 1(st) February 2019.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Ali Mortazavi
------------------------------- -----------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- -----------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Silence Therapeutics Plc
------------------------------- -----------------------------------------------
b) LEI 213800SSURRJBX85SQ91
------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares
instrument, type of instrument
ISIN for Silence Therapeutics plc Ordinary
Identification code Shares GB00B9GTXM62
------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of Options under the Silence Therapeutics
Plc 2018 Long Term Incentive Plan
------------------------------- -----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence 88,620
------------------------------- -----------------------------------------------
d) Aggregated information
- Aggregated volume 88,620 Options
- Price 5 pence
------------------------------- -----------------------------------------------
e) Date of the transaction 2 February, 2018
------------------------------- -----------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- -----------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name David Ellam
------------------------------- -----------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------- -----------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Silence Therapeutics plc
------------------------------- -----------------------------------------------
b) LEI 213800SSURRJBX85SQ91
------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares
instrument, type of instrument
Identification code ISIN for Silence Therapeutics plc Ordinary
Shares GB00B9GTXM62
------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of Options under the Silence Therapeutics
Plc 2018 Long Term Incentive Plan
------------------------------- -----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence 81,301
------------------------------- -----------------------------------------------
d) Aggregated information
- Aggregated volume 81,301 Options
- Price 5 pence
------------------------------- -----------------------------------------------
e) Date of the transaction 2 February 2018
------------------------------- -----------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- -----------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Annalisa Jenkins
------------------------------- -------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Non-Executive Chair
------------------------------- -------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Silence Therapeutics Plc
------------------------------- -------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 5 pence each
instrument, type of instrument
Identification code ISIN for Silence Therapeutics plc Ordinary
Shares GB00B9GTXM62
--------------------------------- -------------------------------------------
b) Nature of the transaction Grant of restricted stock units under the
Silence Therapeutics plc 2018 Non-employee
Long Term Incentive Plan
--------------------------------- -------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence 1,626
--------------------------------- -------------------------------------------
d) Aggregated information
- Aggregated volume 1,626 restricted stock units
- Price 5 pence
--------------------------------- -------------------------------------------
e) Date of the transaction 2 February, 2018
--------------------------------- -------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------- -------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Alistair Gray
------------------------------- -------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- -------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Silence Therapeutics Plc
------------------------------- -------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 5 pence each
instrument, type of instrument
ISIN for Silence Therapeutics plc Ordinary
Identification code Shares GB00B9GTXM62
--------------------------------- -------------------------------------------
b) Nature of the transaction Grant of restricted stock units under the
Silence Therapeutics plc 2018 Non-employee
Long Term Incentive Plan
--------------------------------- -------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence 1,626
--------------------------------- -------------------------------------------
d) Aggregated information
- Aggregated volume 1,626 restricted stock units
- Price 5 pence
--------------------------------- -------------------------------------------
e) Date of the transaction 2 February, 2018
--------------------------------- -------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------- -------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Stephen Parker
------------------------------- -------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- -------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics Plc
------------------------------- -------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 5 pence each
instrument, type of instrument
ISIN for Silence Therapeutics plc
Identification code Ordinary Shares GB00B9GTXM62
--------------------------------- -------------------------------------
b) Nature of the transaction Grant of restricted stock units under
the Silence Therapeutics plc 2018
Non-employee Long Term Incentive
Plan
--------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence 1,626
--------------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 1,626 restricted stock units
- Price 5 pence
--------------------------------- -------------------------------------
e) Date of the transaction 2 February, 2018
--------------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------- -------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Andy Richards
------------------------------- -------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- -------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics Plc
------------------------------- -------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 5 pence each
instrument, type of instrument
ISIN for Silence Therapeutics plc
Identification code Ordinary Shares GB00B9GTXM62
--------------------------------- -------------------------------------
b) Nature of the transaction Grant of restricted stock units under
the Silence Therapeutics plc 2018
Non-employee Long Term Incentive
Plan
--------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence 1,626
--------------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 1,626 restricted stock units
- Price 5 pence
--------------------------------- -------------------------------------
e) Date of the transaction 2 February, 2018
--------------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------- -------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457 6900 Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer Peel Hunt LLP (Nominated Adviser and Tel: +44 (0)20 7418 8900 Broker) James Steel/Oliver Jackson Media Enquiries: Tel: +44 (0) 20 3714 1788 Optimum Strategic Communications Mary Clark/ Eva Haas/Hollie Vile silence@optimumcomms.com
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAFAAEAEPEFF
(END) Dow Jones Newswires
February 02, 2018 06:38 ET (11:38 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
